Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Shares Outstanding (2016 - 2025)

Macrogenics (MGNX) has disclosed Shares Outstanding for 12 consecutive years, with $63.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 0.79% to $63.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.3 million, a 0.79% increase, with the full-year FY2025 number at $63.3 million, up 0.79% from a year prior.
  • Shares Outstanding was $63.3 million for Q4 2025 at Macrogenics, roughly flat from $63.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $63.3 million in Q4 2025 to a low of $60.0 million in Q1 2021.
  • A 5-year average of $62.0 million and a median of $62.0 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: grew 12.68% in 2021, then grew 0.34% in 2022.
  • Macrogenics' Shares Outstanding stood at $61.3 million in 2021, then rose by 0.64% to $61.7 million in 2022, then increased by 0.6% to $62.1 million in 2023, then grew by 1.21% to $62.8 million in 2024, then grew by 0.79% to $63.3 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Shares Outstanding are $63.3 million (Q4 2025), $63.3 million (Q3 2025), and $63.2 million (Q2 2025).